Aura Biosciences
Develops bel-sar, a virus-like drug conjugate for organ-preserving cancer treatment.
$7.40
After-hours close+0.01 (+0.07%)
At close$7.40(−3.96%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 92.39%95.56M sharesInsiders 2.61%2.70M sharesOther 5.00%5.18M shares
Shares outstanding 103.44M · Float 64.51M · 62.4% free float
Institutions13F, as of Jun 30, 2026
150 holders · 95.56M shares · 38 new positions · 97 increased · 28 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.53M | 9.22% | +9.53Mnew | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 7.21M | 6.97% | +2.83M | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 7.10M | 6.86% | +2.00M | Aug 14, 2026 |
| Long Focus Capital Management, LLC | 5.12M | 4.95% | +500.0K | Aug 14, 2026 |
| BlackRock, Inc. | 4.71M | 4.55% | +1.12M | Aug 7, 2026 |
| Adage Capital Partners GP, L.L.C. | 4.64M | 4.49% | −241.1K | Aug 14, 2026 |
| Caligan Partners LP | 4.30M | 4.16% | +4.07M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.10M | 3.96% | +1.86M | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.60% | 4.70M | 13G | Aug 13, 2025 ↗ |
| Frazier Life Sciences Public Fund, L.P. | 6.30% | 4.03M | 13G | Feb 13, 2026 ↗ |
| BlackRock, Inc. | 5.40% | 3.34M | 13G | Oct 17, 2025 ↗ |
| TCG Crossover GP II, LLC | 5.00% | 4.77M | 13G | May 12, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Natalie C. Holles | director, officer: See Remarks | 600.1K | 0.58% | May 19, 2026 |
| Pinos Elisabet de los | director, officer: See Remarks | 575.8K | 0.56% | Mar 3, 2026 |
| Janet Jill Hopkins | officer: Chief Medical Officer | 321.3K | 0.31% | Mar 3, 2026 |
| Anthony S. Gibney | officer: See Remarks | 265.4K | 0.26% | Jun 16, 2026 |
| Mark Plavsic | officer: Chief Technology Officer | 243.7K | 0.24% | Mar 3, 2026 |
| Conor Kilroy | officer: See Remarks | 232.7K | 0.22% | Jul 1, 2026 |
| David Michael Johnson | director | 194.2K | 0.19% | Jun 15, 2026 |
| Amy Elazzouzi | officer: Senior Vice President, Finance | 120.1K | 0.12% | Mar 3, 2026 |
| Antony C. Mattessich | director | 38.5K | 0.04% | Jun 15, 2026 |
| Sapna Srivastava | director | 38.5K | 0.04% | Jun 15, 2026 |
7 people have not refiled in the last 18 months (1.86M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 16, 2026 | Anthony S. Gibneyofficer: See Remarks | Sale | 12,824 | $6.42 | 265,354 |
| May 7, 2026 | Matrix Capital Management Company, LP10 percent owner | Sale | 6,922,870 | $5.64 | 0 |
| Apr 16, 2026 | Conor Kilroyofficer: See Remarks | Sale | 11,738 | $7.02 | 217,835 |
| Feb 17, 2026 | Pinos Elisabet de losdirector, officer: See Remarks | Sale | 47,648 | $5.06 | 409,815 |
| Feb 17, 2026 | Amy Elazzouziofficer: Senior Vice President, Finance | Sale | 8,549 | $5.06 | 75,532 |
| Feb 17, 2026 | Janet Jill Hopkinsofficer: Chief Medical Officer | Sale | 20,401 | $5.06 | 232,284 |
| Feb 17, 2026 | Mark Plavsicofficer: Chief Technology Officer | Sale | 15,890 | $5.05 | 181,397 |
| Feb 17, 2026 | Conor Kilroyofficer: See Remarks | Sale | 12,079 | $5.05 | 167,234 |
| Jan 20, 2026 | Pinos Elisabet de losdirector, officer: See Remarks | Sale | 16,928 | $4.86 | 457,463 |
| Jan 20, 2026 | Amy Elazzouziofficer: Senior Vice President, Finance | Sale | 1,581 | $4.86 | 84,081 |
CongressHouse and Senate disclosures
Not reported.